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UV-induced DNA damage in melano-
cytes is regulated hormonally. What
biological advantage is conferred by
maintaining intermediate levels of
repair that can be upregulated and
downregulated by hormonal factors
produced locally and centrally? Is it
possible that DNA repair is playing a
role in the balance between cell
survival, senescence, and immortaliza-
tion of cancerous melanocytes? Could
reduction of repair mechanisms through
antagonism of MC1R function make
melanocytes or melanoma cells more
vulnerable to immunologic attack (e.g.,
in vitiligo or immunotherapy for mela-
noma) or sensitize these cells to
traditional DNA damaging chemother-
apeutics? These questions and ideas are
certainly not the only ones that could be
raised, but they will hopefully increase
readers’ appreciation of the clinical
relevance of this work as well as the
implications that extend from the ﬁelds
of pigmentation and melanoma to
inﬂammation, immunology, and, even,
infectious disease.
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Melanocyte Regeneration in Vitiligo
Requires WNT beneath their Wings
John E. Harris1
Melanocytes in patients with vitiligo possess intrinsic abnormalities that
contribute to its pathogenesis. Regazzetti et al. report that CXCL10 expression
reﬂects subtle inﬂammation in normal-appearing skin but not in stable
depigmented lesions, supporting the hypothesis that melanocytes themselves
initiate autoimmune inﬂammation prior to clinically evident disease. In addition,
they ﬁnd that oxidative stress in melanocytes impairs WNT signaling and that
targeting this pathway induces melanoblast differentiation. Thus, activating the
WNT pathway may serve as an adjunctive strategy to support repigmentation in
patients with vitiligo.
Journal of Investigative Dermatology (2015) 135, 2921–2923. doi:10.1038/jid.2015.372
Regazzetti et al. (2015) report that WNT
signaling is impaired in lesional and
nonlesional skin of patients with vitiligo.
Because WNT signaling promotes the
differentiation of melanocyte precursors
in skin (Yamada et al., 2013), impaired
signaling may affect the ability of
melanocytes to proliferate and differ-
entiate into functional melanocytes
during therapeutic repigmentation.
Current treatments for vitiligo include
topical anti-inﬂammatory compounds,
such as corticosteroids and calcineurin
inhibitors, which inhibit autoimmune
responses, as well as narrow-band ultra-
violet radiation B (nbUVB) (Ezzedine
et al., 2015), which likely inhibits auto-
immunity and promotes melanocyte
regeneration. Repigmentation in vitiligo
begins within 6–12 weeks after initiating
treatment, and it frequently occurs in a
perifollicular pattern (Figure 1). A recent
study has reported that nbUVB treatment
of vitiligo is associated with proliferation,
migration, and differentiation of melano-
cytes in the hair follicles and epidermis
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of lesional skin (Goldstein et al., 2015).
The current study suggests that impaired
WNT signaling in vitiligo slows down
this process and that promoting this
pathway may improve repigmentation
by enhancing melanocyte differentiation.
It is now well established that melano-
cytes in vitiligo have increased oxidative
stress, reﬂected by elevated levels of
reactive oxidative species in cultured
cells in vitro and within the epidermis
in vivo (Glassman, 2011; Ezzedine et al.,
2015). This may have an important role
in its pathogenesis, possibly by initiating
inﬂammation and autoimmunity in the
skin (Richmond et al., 2013). However,
the current study now indicates that
oxidative stress may also be partly
responsible for impaired WNT signaling,
as melanocytes exposed to oxidative
stress in vitro decreased the expression
of WNT family members. Thus, oxidative
stress may both promote autoimmune
inﬂammation and impair melano-
cyte regeneration during treatment. The
authors reasoned that, if WNT signaling
were important for melanocyte differen-
tiation but impaired in patients with
vitiligo, then pharmacological activators
of this pathway might help promote
melanocyte differentiation in the skin.
Indeed, the authors demonstrated that
members of the WNT signaling pathway
are induced in the skin by a chemical
WNT agonist and two antagonists of
GSK-β (a negative regulator of the path-
way) and that this treatment promotes the
differentiation of melanoblast precursors
in skin affected by vitiligo. They suggest
that stimulating WNT signaling may
serve as an adjunct to current therapies.
It is possible that WNT activators could
synergize with anti-inﬂammatory treat-
ments to simultaneously shut down
autoimmunity and promote melanocyte
regeneration.
We previously reported transcriptional
differences in the lesional skin of vitiligo
patients compared with healthy control
skin, but focused on lesions with active
inﬂammation to reveal the cytokine
and chemokine patterns responsible for
driving autoimmunity. This approach
revealed an IFN-γ-speciﬁc signature,
and CXCL10, an IFN-γ-induced chemo-
kine, was the most highly expressed gene
in lesional skin. We further determined
that CXCL10 was elevated in a mouse
model of vitiligo that we developed, and
that it was required functionally for both
the progression of vitiligo as well as for
the maintenance of disease, as neutraliz-
ing CXCL10 both prevented depigmenta-
tion as well as reversed established
disease (Rashighi et al., 2014). The
current study by Regazzetti et al. also
found that CXCL10 is elevated in
perilesional skin in vitiligo, although the
magnitude of expression was lower than
in our study. This is likely due to the fact
that we proﬁled only lesional skin with a
signiﬁcant mononuclear inﬁltrate by
histology, whereas the present study
proﬁled perilesional skin indiscrimi-
nately, which would usually include
sites with very mild inﬂammation.
However, the current study went
further, analyzing also stably depigmen-
ted and normally pigmented skin from
vitiligo, and it compared these results
with normal, control skin as well. This
revealed that the expression of CXCL10
is also mildly elevated in nonlesional,
normally pigmented skin in vitiligo,
when compared with healthy control
skin, which suggests that subtle inﬂam-
mation is present even before the
appearance of clinically evident lesions.
This may indicate a predisposition in all
of the skin of patients to develop
vitiligo, and this may reﬂect the ability
of tolerance mechanisms to keep low-
level inﬂammation “in check”, thereby
preventing new lesions from appearing.
Previous studies have reported an
important role for T-regulatory cells in
controlling the spread of depigmenta-
tion in mouse models of vitiligo (Gregg
et al., 2010; Chatterjee et al., 2014),
which may be a key mechanism that
controls further depigmentation. Impor-
tantly, in contrast to normally pigmen-
ted skin, completely depigmented skin
from patients with vitiligo (old, inactive
lesions) did not have elevated CXCL10,
suggesting that the presence of melano-
cytes was required to fuel the low-level
inﬂammation. Melanocytes in vitiligo
are not simply targets of autoimmunity;
rather, they contain intrinsic defects that
help initiate the autoimmune destruc-
tion that is observed in vitiligo (PasseronFigure 1. Perifollicular repigmentation in a patient with vitiligo during nbUVB phototherapy.
Clinical Implications
● Oxidative stress, which is elevated in melanocytes from patients with
vitiligo, may directly inhibit WNT activation. Because WNT signaling is
important for melanoblast differentiation, this impaired signaling may
inhibit melanocyte regeneration during therapy.
● Therapeutic WNT activation might serve as an adjunctive therapeutic
strategy employing anti-inﬂammatory agents to support melanocyte
regeneration.
● CXCL10 is expressed in normally pigmented skin in patients with vitiligo
but not in completely depigmented skin, from which melanocytes are
absent. This supports the hypothesis that melanocytes themselves initiate
autoimmune inﬂammation in vitiligo.
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and Ortonne, 2012; Richmond et al.,
2013). Future studies may reveal how
“abnormal” melanocytes promote auto-
immunity in vitiligo, and speciﬁcally
how CXCL10 is initially induced in
disease.
Targeted therapy may
promote repigmentation
in vitiligo by serving as
the ‘WNT beneath the
wings’ of regenerating
melanocytes.
The study by Regazzetti et al. (2015)
conﬁrms our ﬁndings that CXCL10 is
expressed within active lesional skin in
vitiligo (Rashighi et al., 2014), and,
further, it suggests that subtle inﬂamma-
tion is ongoing in even normally pig-
mented skin. In addition, this study
connects oxidative stress in melano-
cytes to the WNT signaling pathway,
revealing that intrinsic defects in
melanocytes from such patients likely
include impaired WNT signaling.
Finally, the authors hypothesize that
pharmacological activation of the
pathway could help promote melano-
cyte differentiation and repigmentation
during treatment, serving as the “WNT
beneath the wings” of regenerating
melanocytes, which must go through a
series of steps, beginning with differ-
entiation of melanocyte precursors in
the hair follicles or other niches of the
skin and then progressing through prolife-
ration, migration, and further differentia-
tion into functional melanocytes. The
study used an innovative new ex vivo
vitiligo skin culture model to demonstrate
that WNT activators begin this process by
differentiating melanoblasts but, because
of the limited time that the cultures could
be maintained ex vivo, the authors were
unable to determine whether this would
progress to promote fully functional
melanocytes. The role of WNT signal-
ing in events downstream of melano-
cyte differentiation is not clear, and future
studies will hopefully to assess this in
order to translate these results into new
treatments.
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Microenvironment-Driven Resistance
to BRAF Inhibition Comes of Age
Dinoop Ravindran Menon1 and Helmut Schaider1,2
Increasingly comprehensive observations indicate that the tumor microenviron-
ment contributes to drug resistance toward small molecule inhibitors. Fedorenko
et al. describe a role for ﬁbroblasts in creating a favorable niche for melanoma
cell survival if treated with the BRAF inhibitor vemurafenib. TGF-β released by
vemurafenib-treated melanoma cells stimulated ﬁbroblasts for increased
α-smooth muscle actin, neuregulin (NRG), and ﬁbronectin expression.
Off-target effects of vemurafenib led to paradoxical secretion of hepatocyte
growth factor (HGF) by ﬁbroblasts. Combined inhibition of BRAF/MET/HER
kinases was insufﬁcient to reverse the protective effect of the ﬁbroblasts,
whereas reversal was achieved by combined BRAF/PI3K inhibition. A thorough
understanding of the complex spatiotemporal interactions in tumor microenvir-
onments holds promise for improved targeting using combination therapies in
patients with melanoma.
Journal of Investigative Dermatology (2015) 135, 2923–2925. doi:10.1038/jid.2015.373
Small molecule inhibitors have brought
about a strategic shift in the way
melanomas are treated. Melanoma
patients harboring BRAF mutations in
particular have reaped signiﬁcant beneﬁt
from small molecule BRAF–MEK
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